Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

3.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

633
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Diagnostic Code Priority With Identification of True Cardiac Arrest in Patients Presenting to the Emergency Department.

Journal of cardiovascular electrophysiology·2026
Same author

Novel machine learning fusion architectures integrating electrocardiogram representations: applications to acute coronary event detection.

European heart journal. Digital health·2026
Same author

Prognostic importance of septal deformation patterns and lateral wall function in patients with heart failure and left bundle branch block receiving cardiac resynchronization therapy.

European heart journal. Imaging methods and practice·2026
Same author

Exploratory Laparotomy After Routine Cardiac Surgery: Results From 17,000 Patients.

World journal of surgery·2026
Same author

Mortality, Hospitalization, and Cardiac Interventions Among Patients With Mitral Valve Prolapse <65 Years of Age.

Journal of the American Heart Association·2026
Same author

Outcomes of Septal Versus Non-Septal Right Ventricular Pacemaker Leads as Adjudicated by CT Imaging.

Journal of cardiovascular electrophysiology·2026

Related Experiment Video

Updated: Apr 10, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K

Long-Term Outcomes With Class 1C Antiarrhythmic Drug Use in Atrial Fibrillation.

Aditya Bhonsale1, Yisi Wang2, Floyd Thoma2

  • 1Division of Cardiac Electrophysiology University of Pittsburgh Medical Center Pittsburgh PA USA.

Journal of the American Heart Association
|April 9, 2026
PubMed
Summary

Rhythm control with class 1C antiarrhythmic drugs (AADs) in atrial fibrillation (AF) patients improved survival and reduced stroke hospitalizations compared to rate control. This study highlights the cardiovascular benefits of class 1C AADs in managing AF.

Keywords:
antiarrhythmicatrial fibrillationoutcome

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

14.0K

Related Experiment Videos

Last Updated: Apr 10, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

14.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Rhythm control using class 1C antiarrhythmic drugs (AADs) is common for atrial fibrillation (AF).
  • The comparative cardiovascular benefits of rhythm control versus rate control strategies in AF remain unclear.

Purpose of the Study:

  • To evaluate the long-term outcomes of using class 1C AADs for rhythm control compared to rate control in adult patients with AF.
  • To assess the association of class 1C AADs with all-cause death, stroke, heart failure, and major bleeding.

Main Methods:

  • Retrospective analysis of 100,748 adult AF patients from 2010-2023.
  • Propensity score matching was used to balance 36 clinical characteristics between groups.
  • Adjusted Cox modeling with competing risk analysis compared outcomes between rhythm control (class 1C AADs) and rate control strategies.

Main Results:

  • Class 1C AAD use (n=5239) was associated with significantly lower all-cause death (HR 0.65) and stroke hospitalization (HR 0.82) compared to rate control.
  • Benefits were modified by age, CHA2DS2-VASc score, and comorbidity burden.
  • Patients aged 65-80 receiving class 1C AADs experienced less heart failure and major bleeding.

Conclusions:

  • In a real-world North American registry, class 1C AADs for rhythm control in AF patients were linked to improved survival and reduced stroke hospitalizations.
  • These findings suggest a potential cardiovascular benefit of rhythm control with class 1C AADs over rate control in AF management.